Third trial of Repatha reveals positive results
The trial, GAUSS-3, used as subjects patients with high cholesterol who could not tolerate statins. Repatha was shown to reduce low-density lipoprotein cholesterol (LDL-C) after 22 to 24 weeks of treatment.
Repatha is an injectable proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor indicated for the treatment of patients with high cholesterol who cannot use statins because of muscle-related side effects.
"The positive results from the GAUSS-3 study contribute to the growing body of evidence supporting Repatha as an innovative treatment option for patients who have not been able to adequately lower their LDL cholesterol through diet and statins alone," Dr. Sean Harper, executive vice president of research and development at Amgen, said. "Many patients with high LDL cholesterol are unable to tolerate effective doses of statins, and the findings from the rigorously designed GAUSS-3 study confirm the results in the previous GAUSS studies. We look forward to exploring these data further."
The trial also assessed Repatha's safety and tolerability.
Details concerning the trial, as well as additional information about the therapy, are available online at www.repatha.com.
Organizations in this story
Amgen Inc. 1 Amgen Center Dr Thousand Oaks, CA 91320